within Pharmacolibrary.Drugs.D_Dermatologicals.D01A_AntifungalsForTopicalUse.D01AA02_Natamycin;

model Natamycin
  extends Pharmacolibrary.Drugs.ATC.D.D01AA02;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>D01AA02</td></tr><td>route:</td><td>topical</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Natamycin is a polyene macrolide antifungal agent, primarily used to treat fungal infections of the skin, mucous membranes, and eyes. It is approved for topical use, including ophthalmic and cutaneous fungal infections, and is also used as a food preservative due to its effective antifungal properties.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetics for healthy adults after topical ocular administration; no published full human systemic PK studies available, as natamycin is minimally absorbed systemically when administered topically.</p><h4>References</h4><ol><li><p>Zhao, X, et al., &amp; Lu, H (2018). Comparison of the Ocular Penetration and Pharmacokinetics Between Natamycin and Voriconazole After Topical Instillation in Rabbits. <i>Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics</i> 34(6) 460–467. DOI:<a href=&quot;https://doi.org/10.1089/jop.2017.0139&quot;>10.1089/jop.2017.0139</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29792548/&quot;>https://pubmed.ncbi.nlm.nih.gov/29792548</a></p></li><li><p>Velpandian, T, et al., &amp; Halder, N (2021). Novel water soluble sterile natamycin formulation (Natasol) for fungal keratitis. <i>European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences</i> 163 105857–None. DOI:<a href=&quot;https://doi.org/10.1016/j.ejps.2021.105857&quot;>10.1016/j.ejps.2021.105857</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33882328/&quot;>https://pubmed.ncbi.nlm.nih.gov/33882328</a></p></li><li><p>Kaur, IP, &amp; Kakkar, S (2010). Topical delivery of antifungal agents. <i>Expert opinion on drug delivery</i> 7(11) 1303–1327. DOI:<a href=&quot;https://doi.org/10.1517/17425247.2010.525230&quot;>10.1517/17425247.2010.525230</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/20961206/&quot;>https://pubmed.ncbi.nlm.nih.gov/20961206</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Natamycin;
